Occult gastrointestinal bleeding in high-risk intensive care unit patients receiving antacid prophylaxis: frequency and significance.
Gastroccult reagent was used every 4 h to detect blood in gastric juice in 41 ICU patients at risk of GI bleeding (GB) and receiving antacid prophylaxis (gastric pH greater than 3.5). Of the present patients, 27% (11/41) had at least one episode of occult GB (three consecutive positive determinations; a total of 14 episodes). Endoscopy identified acute gastroduodenal mucosal lesions (stress ulcers) as the most frequent lesion in this group (eight patients). Sepsis was the most frequent underlying condition associated with occult GB due to stress ulcer. Hematemesis occurred in 36% (4/11) of patients with occult GB and was due to stress ulcer in three patients and to benign gastric tumor in one. No overt GB occurred in the absence of previous occult GB. We conclude that: a) risk of GB persists in critically ill ICU patients in spite of antacid prophylaxis (gastric pH greater than 3.5); b) high-risk patients can be identified through periodic testing for the presence of blood in gastric juice using the reagent; c) when occult GB occurs, treatment should be based on the endoscopy results. In the absence of acute gastroduodenal mucosal lesions, antacid prophylaxis should not be modified, and specific treatment of the identified lesion(s) should be initiated. In the presence of stress lesions, antacid prophylaxis should be reinforced if the pH of the gastric content is less than 3.5 and a septic complication should be actively sought if the pH is greater than 3.5.
Derrida
S
S
Intensive Care Unit, Centre Hospitalier Emile-Roux, Eaubonne, France.
Nury
B
B
Slama
R
R
Marois
F
F
Moreau
R
R
Soupison
T
T
Sicot
C
C
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000535:Aluminum / Q000627:therapeutic use; D017607:Aluminum Compounds; D000536:Aluminum Hydroxide / Q000627:therapeutic use; D000863:Antacids / Q000627:therapeutic use*; D003422:Critical Care; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D005745:Gastric Acidity Determination; D006471:Gastrointestinal Hemorrhage / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000401:mortality; D006801:Humans; D008276:Magnesium Hydroxide / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009780:Occult Blood; D010710:Phosphates / Q000627:therapeutic use; D012307:Risk Factors; D012841:Simethicone / Q000627:therapeutic use
D017607:Aluminum Compounds; D000863:Antacids; D004338:Drug Combinations; D010710:Phosphates; C008570:aluminum hydroxide, magnesium hydroxide, simethicone drug combination; D000536:Aluminum Hydroxide; D012841:Simethicone; D000535:Aluminum; C012714:aluminum phosphate; D008276:Magnesium Hydroxide